pentobarbital will minimize the level or impact of alfuzosin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unknown.
pentobarbital will lower the level or influence of trazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep an eye on.
Reserve concomitant prescribing of those drugs in sufferers for whom other treatment solutions are insufficient. Limit dosages and durations for the bare minimum necessary. Keep track of closely for signs of respiratory despair and sedation.
Caution is warranted for individuals with renal and hepatic impairment. Even though the producer will not give particular dosage adjustment recommendations for renal impairment, checking kidney purpose when administering substantial doses or conducting extended cure is important.
pentobarbital will minimize the level or outcome of fostemsavir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
CYP3A4 inducers may possibly raise the development of the neurotoxic/nephrotoxic ifosfamide metabolite, chloroacetaldehyde. Carefully monitor people having ifosfamide with CYP3A4 inducers for toxicities and contemplate dose adjustment.
fentanyl transdermal and pentobarbital equally raise sedation. Stay clear of or Use Alternate Drug. Limit use to sufferers for whom different cure solutions are inadequate
pentobarbital will minimize the extent or outcome of ambrisentan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unknown.
pentobarbital will lower the extent or result of vinorelbine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unknown.
pentobarbital will lessen click here the level or outcome of sufentanil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Importance Unknown.
pentobarbital will minimize the level or impact of fedratinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Impact of coadministering a solid CYP3A4 inducer with fedratinib has not been examined.
pentobarbital improves toxicity of ifosfamide by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. CYP3A4 inducers may increase the metabolism of ifosfamide to its active alkylating metabolites.
pentobarbital will lower the extent or effect of oliceridine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. If coadministration having a CYP3A4 inducer is important, take into consideration increasing oliceridine dose till secure drug effects are attained; keep an eye on for indications of opioid withdrawal.
Reserve concomitant prescribing of these prescription drugs in clients for whom other remedy options are insufficient. Limit dosages and durations to the least expected. Check closely for indications of respiratory melancholy and sedation.